7 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 6 with minor changes only.
Primary completion pushed from Dec 2026 to Aug 2027
Shandong Suncadia Medicine Co., Ltd.Phase 3 NCT07024173 Registry history of NCT07024173 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Shandong Suncadia Medicine Co., Ltd.Phase 2 NCT07470983 Registry history of NCT07470983 on ClinicalTrials.gov (opens the registry)
Trial completed
Shandong Suncadia Medicine Co., Ltd.Phase 1 NCT07608705 Registry history of NCT07608705 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Oct 2026 to Aug 4, 2026
Shandong Suncadia Medicine Co., Ltd.Phase 1 NCT07322016 Registry history of NCT07322016 on ClinicalTrials.gov (opens the registry)
Trial completed
Shandong Suncadia Medicine Co., Ltd.Phase 1 NCT07351968 Registry history of NCT07351968 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Shandong Suncadia Medicine Co., Ltd.Phase 1 NCT07639905 Registry history of NCT07639905 on ClinicalTrials.gov (opens the registry)
Trial completed
Shandong Suncadia Medicine Co., Ltd.Phase 1 NCT07479641 Registry history of NCT07479641 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-15 | NCT07876596 A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 | Phase 1 | Not Yet Recruiting |
| Phase 1 | 10 | |
| Phase 1/2 | 5 | |
| Phase 2 | 12 | |
| Phase 2/3 | 2 | |
| Phase 3 | 8 |
Breast Cancer (8) · Heart Disease (7) · Chronic Kidney Disease (3) · Heart Failure (3) · Obesity (3) · Hypertension (2) · Lung Cancer (1) · Non-Small Cell Lung Cancer (NSCLC) (1) · Pancreatic Cancer (1) · Ulcerative Colitis (1)